Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study

Madan H. Jagasia, J. P. Greer, D. S. Morgan, Shin Mineishi, A. A. Kassim, K. L. Ruffner, H. Chen, F. G. Schuening

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pegfilgrastim is equivalent to daily filgrastim after standard dose chemotherapy in decreasing the duration of neutropenia. Daily filgrastim started within 1-4 days after autologous stem cell transplant (ASCT) leads to significant decrease in time to neutrophil engraftment. We undertook a study of pegfilgrastim after high-dose chemotherapy (HDC) and ASCT. In all, 38 patients with multiple myeloma or lymphoma, eligible to undergo HDC and ASCT, were enrolled. Patients received a single dose of 6mg pegfilgrastim subcutaneously 24h after ASCT. There were no adverse events secondary to pegfilgrastim. All patients engrafted neutrophils and platelets with a median of 10 and 18 days, respectively. The incidence of febrile neutropenia was 49% (18/37). Neutrophil engraftment results were compared to a historical cohort of patients who received no growth factors or prophylactic filgrastim after ASCT. Time to neutrophil engraftment using pegfilgrastim was comparable to daily filgrastim and was shorter than in a historical group receiving no filgrastim (10 vs 13.7 days, P < 0.001). Pegfilgrastim given as a single fixed dose of 6 mg appears to be safe after HDC and ASCT. It accelerates neutrophil engraftment comparable to daily filgrastim after ASCT. Pegfilgrastim may be convenient to use in outpatient transplant units.

Original languageEnglish (US)
Pages (from-to)1165-1169
Number of pages5
JournalBone Marrow Transplantation
Volume35
Issue number12
DOIs
StatePublished - Jun 1 2005

Fingerprint

Stem Cells
Transplants
Drug Therapy
Neutrophils
Febrile Neutropenia
Peripheral Blood Stem Cells
pegfilgrastim
Neutropenia
Multiple Myeloma
Filgrastim
Lymphoma
Intercellular Signaling Peptides and Proteins
Outpatients
Blood Platelets
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Jagasia, M. H., Greer, J. P., Morgan, D. S., Mineishi, S., Kassim, A. A., Ruffner, K. L., ... Schuening, F. G. (2005). Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study. Bone Marrow Transplantation, 35(12), 1165-1169. https://doi.org/10.1038/sj.bmt.1704994
Jagasia, Madan H. ; Greer, J. P. ; Morgan, D. S. ; Mineishi, Shin ; Kassim, A. A. ; Ruffner, K. L. ; Chen, H. ; Schuening, F. G. / Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant : Phase II study. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 12. pp. 1165-1169.
@article{21b84a8429a8496f85d497655b7dd4ac,
title = "Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study",
abstract = "Pegfilgrastim is equivalent to daily filgrastim after standard dose chemotherapy in decreasing the duration of neutropenia. Daily filgrastim started within 1-4 days after autologous stem cell transplant (ASCT) leads to significant decrease in time to neutrophil engraftment. We undertook a study of pegfilgrastim after high-dose chemotherapy (HDC) and ASCT. In all, 38 patients with multiple myeloma or lymphoma, eligible to undergo HDC and ASCT, were enrolled. Patients received a single dose of 6mg pegfilgrastim subcutaneously 24h after ASCT. There were no adverse events secondary to pegfilgrastim. All patients engrafted neutrophils and platelets with a median of 10 and 18 days, respectively. The incidence of febrile neutropenia was 49{\%} (18/37). Neutrophil engraftment results were compared to a historical cohort of patients who received no growth factors or prophylactic filgrastim after ASCT. Time to neutrophil engraftment using pegfilgrastim was comparable to daily filgrastim and was shorter than in a historical group receiving no filgrastim (10 vs 13.7 days, P < 0.001). Pegfilgrastim given as a single fixed dose of 6 mg appears to be safe after HDC and ASCT. It accelerates neutrophil engraftment comparable to daily filgrastim after ASCT. Pegfilgrastim may be convenient to use in outpatient transplant units.",
author = "Jagasia, {Madan H.} and Greer, {J. P.} and Morgan, {D. S.} and Shin Mineishi and Kassim, {A. A.} and Ruffner, {K. L.} and H. Chen and Schuening, {F. G.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1038/sj.bmt.1704994",
language = "English (US)",
volume = "35",
pages = "1165--1169",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

Jagasia, MH, Greer, JP, Morgan, DS, Mineishi, S, Kassim, AA, Ruffner, KL, Chen, H & Schuening, FG 2005, 'Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: Phase II study', Bone Marrow Transplantation, vol. 35, no. 12, pp. 1165-1169. https://doi.org/10.1038/sj.bmt.1704994

Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant : Phase II study. / Jagasia, Madan H.; Greer, J. P.; Morgan, D. S.; Mineishi, Shin; Kassim, A. A.; Ruffner, K. L.; Chen, H.; Schuening, F. G.

In: Bone Marrow Transplantation, Vol. 35, No. 12, 01.06.2005, p. 1165-1169.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant

T2 - Phase II study

AU - Jagasia, Madan H.

AU - Greer, J. P.

AU - Morgan, D. S.

AU - Mineishi, Shin

AU - Kassim, A. A.

AU - Ruffner, K. L.

AU - Chen, H.

AU - Schuening, F. G.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Pegfilgrastim is equivalent to daily filgrastim after standard dose chemotherapy in decreasing the duration of neutropenia. Daily filgrastim started within 1-4 days after autologous stem cell transplant (ASCT) leads to significant decrease in time to neutrophil engraftment. We undertook a study of pegfilgrastim after high-dose chemotherapy (HDC) and ASCT. In all, 38 patients with multiple myeloma or lymphoma, eligible to undergo HDC and ASCT, were enrolled. Patients received a single dose of 6mg pegfilgrastim subcutaneously 24h after ASCT. There were no adverse events secondary to pegfilgrastim. All patients engrafted neutrophils and platelets with a median of 10 and 18 days, respectively. The incidence of febrile neutropenia was 49% (18/37). Neutrophil engraftment results were compared to a historical cohort of patients who received no growth factors or prophylactic filgrastim after ASCT. Time to neutrophil engraftment using pegfilgrastim was comparable to daily filgrastim and was shorter than in a historical group receiving no filgrastim (10 vs 13.7 days, P < 0.001). Pegfilgrastim given as a single fixed dose of 6 mg appears to be safe after HDC and ASCT. It accelerates neutrophil engraftment comparable to daily filgrastim after ASCT. Pegfilgrastim may be convenient to use in outpatient transplant units.

AB - Pegfilgrastim is equivalent to daily filgrastim after standard dose chemotherapy in decreasing the duration of neutropenia. Daily filgrastim started within 1-4 days after autologous stem cell transplant (ASCT) leads to significant decrease in time to neutrophil engraftment. We undertook a study of pegfilgrastim after high-dose chemotherapy (HDC) and ASCT. In all, 38 patients with multiple myeloma or lymphoma, eligible to undergo HDC and ASCT, were enrolled. Patients received a single dose of 6mg pegfilgrastim subcutaneously 24h after ASCT. There were no adverse events secondary to pegfilgrastim. All patients engrafted neutrophils and platelets with a median of 10 and 18 days, respectively. The incidence of febrile neutropenia was 49% (18/37). Neutrophil engraftment results were compared to a historical cohort of patients who received no growth factors or prophylactic filgrastim after ASCT. Time to neutrophil engraftment using pegfilgrastim was comparable to daily filgrastim and was shorter than in a historical group receiving no filgrastim (10 vs 13.7 days, P < 0.001). Pegfilgrastim given as a single fixed dose of 6 mg appears to be safe after HDC and ASCT. It accelerates neutrophil engraftment comparable to daily filgrastim after ASCT. Pegfilgrastim may be convenient to use in outpatient transplant units.

UR - http://www.scopus.com/inward/record.url?scp=21244460393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244460393&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704994

DO - 10.1038/sj.bmt.1704994

M3 - Article

C2 - 15880129

AN - SCOPUS:21244460393

VL - 35

SP - 1165

EP - 1169

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -